Participating insurers reduced prior authorization requirements by 11% overall, equating to approximately 6.5 million fewer requests, with Medicare Advantage experiencing a greater than 15% reduction.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, ...
Home-based oncology transforms practice transformation with clear bagging, protecting Medicare reimbursement, provider ...
UChicago Medicine’s Obada Shamaa, MD, PhD, discusses why bronchiectasis is underrecognized and how to personalize airway ...
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know ...
Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of ...
A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes ...
Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 ...
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and ...
October's FDA approvals brought notable advances beyond oncology, adding new treatment options in allergy and immunology, ...
A gradient boosting model identified MASLD in lean adults with an AUC of 0.779, using 8 routine clinical measurements.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results